News

Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

September 06, 2022

REDWOOD CITY, Calif. , Sept. 06, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...

Read More

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 10, 2022

REDWOOD CITY, Calif. , Aug. 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...

Read More

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

July 20, 2022

FDA acknowledges that data from a randomized withdrawal period of Study C602 have the potential ...

Read More